国资赋能,并购升温:我国生物医药在寒冬中破冰前行

21世纪经济报道
05 Feb

2024年,对于中国生物医药企业而言,似乎尚未走出“资本寒冬”。医药魔方数据显示,中国医疗健康领域一级市场2024年共发生1465起融资事件,同比下降26.75%,融资金额总计736.97亿元,同比下降10.4%。  2025年,不少投资人依旧怀抱乐观预期,在不确定中寻找方向。开年首月,约81家投资机构在生物医药领域有所出手,全部融资事件(不含并购)总融资额达到103.98亿元。在这背后,国资背景...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10